A. Parker Ruhl

A. Parker Ruhl

Auto-generated profile, based on publicly available information

A. Parker Ruhl

Physiology Unit, Laboratory of Malaria and Vector Research National Institute of Allergy and Infectious Diseases Rockville Maryland USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2017 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
ARA. Parker Ruhl
A. Parker Ruhl
MHMinxuan Huang
Minxuan Huang
ECElizabeth Colantuoni
Elizabeth Colantuoni
TKTaruja Karmarkar
Taruja Karmarkar
VDVictor D. Dinglas
Victor D. Dinglas
DNDale M. Needham
Dale M. Needham

1 September 2019 in Annals of the American Thoracic Society
Verified
Journal Article
Open access
ARA. Parker Ruhl
A. Parker Ruhl
SSSara Sadreameli
Sara Sadreameli
JAJulian L. Allen
Julian L. Allen
DBDebra P. Bennett
Debra P. Bennett
ACAndrew Campbell
Andrew Campbell
EKElizabeth S. Klings
Elizabeth S. Klings
Background: Pulmonary complications of sickle cell disease (SCD) are diverse and encompass acute and chronic disease. The understanding of the natural history of pulmonary complications of SCD is limited, no specific therapies exist, and these complications are a primary cause of morbidity and mortality. Methods: We gathered a multidisciplinary group of pediatric and adult hematologists, pulmonologists, and emergency medicine physicians with expertise in SCD-related lung disease along with an SCD patient advocate for an American Thoracic Society–sponsored workshop to review the literature and identify key unanswered clinical and research questions. Participants were divided into four subcommittees on the basis of expertise: 1) acute chest syndrome, 2) lower airways disease and pulmonary function, 3) sleep-disordered breathing and hypoxia, and 4) pulmonary vascular complications of SCD. Before the workshop, a comprehensive literature review of each subtopic was conducted. Clinically important questions were developed after literature review and were finalized by group discussion and consensus. Results: Current knowledge is based on small, predominantly observational studies, few multicenter longitudinal studies, and even fewer high-quality interventional trials specifically targeting the pulmonary complications of SCD. Each subcommittee identified the three or four most important unanswered questions in their topic area for researchers to direct the next steps of clinical investigation. Conclusions: Important and clinically relevant questions regarding sickle cell lung disease remain unanswered. High-quality, multicenter, longitudinal studies and randomized clinical trials designed and implemented by teams of multidisciplinary clinician-investigators are needed to improve the care of individuals with SCD.

1 February 2017 in Critical Care Medicine
Verified
Journal Article
Closed access
ARA. Parker Md Ruhl
A. Parker Md Ruhl
MHMinxuan ScM Huang
Minxuan ScM Huang
ECElizabeth Colantuoni
Elizabeth Colantuoni
RLRobert K. Lord
Robert K. Lord
VDVictor D. Dinglas
Victor D. Dinglas
DNDale M. Fcpa Needham
Dale M. Fcpa Needham
Objective: To evaluate the time-varying relationship of annual physical, psychiatric, and quality of life status with subsequent inpatient healthcare resource use and estimated costs. Design: Five-year longitudinal cohort study. Setting: Thirteen ICUs at four teaching hospitals. Patients: One hundred thirty-eight patients surviving greater than or equal to 2 years after acute respiratory distress syndrome. Interventions: None. Measurements and Main Results: Postdischarge inpatient resource use data (e.g., hospitalizations, skilled nursing, and rehabilitation facility stays) were collected via a retrospective structured interview at 2 years, with prospective collection every 4 months thereafter, until 5 years postacute respiratory distress syndrome. Adjusted odds ratios for hospitalization and relative medians for estimated episode of care costs were calculated using marginal longitudinal two-part regression. The median (interquartile range) number of inpatient admission hospitalizations was 4 (2–8), with 114 patients (83%) reporting greater than or equal to one hospital readmission. The median (interquartile range) estimated total inpatient postdischarge costs over 5 years were $58,500 ($19,700–157,800; 90th percentile, $328,083). Better annual physical and quality of life status, but not psychiatric status, were associated with fewer subsequent hospitalizations and lower follow-up costs. For example, greater grip strength (per 6 kg) had an odds ratio (95% CI) of 0.85 (0.73–1.00) for inpatient admission, with 23% lower relative median costs, 0.77 (0.69–0.87). Conclusions: In a multisite cohort of long-term acute respiratory distress syndrome survivors, better annual physical and quality of life status, but not psychiatric status, were associated with fewer hospitalizations and lower healthcare costs.

20 December 2018 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
JMJessica Manning
Jessica Manning
FOFabiano Oliveira
Fabiano Oliveira
DPDaniel Parker
Daniel Parker
CAChanaki Amaratunga
Chanaki Amaratunga
DKDara Kong
Dara Kong
RLRithea Leang
Rithea Leang
Mosquito-borne arboviruses, like dengue virus, continue to cause significant global morbidity and mortality, particularly in Southeast Asia. When the infectious mosquitoes probe into human skin for a blood meal, they deposit saliva containing a myriad of pharmacologically active compounds, some of which alter the immune response and influence host receptivity to infection, and consequently, the establishment of the virus. Previous reports have highlighted the complexity of mosquito vector-derived factors and immunity in the success of infection. Cumulative evidence from animal models and limited data from humans have identified various vector-derived components, including salivary components, that are co-delivered with the pathogen and play an important role in the dissemination of infection. Much about the roles and effects of these vector-derived factors remain to be discovered. We describe a longitudinal, pagoda (community)-based pediatric cohort study to evaluate the burden of dengue virus infection and document the immune responses to salivary proteins of Aedes aegypti, the mosquito vector of dengue, Zika, and chikungunya viruses. The study includes community-based seroprevalence assessments in the peri-urban town of Chbar Mon in Kampong Speu Province, Cambodia. The study aims to recruit 771 children between the ages of 2 and 9 years for a three year period of longitudinal follow-up, including twice per year (rainy and dry season) serosurveillance for dengue seroconversion and Ae. aegypti salivary gland homogenate antibody intensity determinations by ELISA assays. Diagnostic tests for acute dengue, Zika and chikungunya viral infections will be performed by RT-PCR. This study will serve as a foundation for further understanding of mosquito saliva immunity and its impact on Aedes-transmitted arboviral diseases endemic to Cambodia. NCT03534245 registered on 23 May 2018.

1 January 2022 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
ARA. Parker Ruhl
A. Parker Ruhl
NJNeal Jeffries
Neal Jeffries
YYYu Yang
Yu Yang
RNRakhi P. Naik
Rakhi P. Naik
APAmit Patki
Amit Patki
HAHans Ackerman
Hans Ackerman
Significance Statement: Resistance artery endothelial cells express α-globin, which limits nitric oxide signaling and enhances α-adrenergic–mediated vasoconstriction—two signaling pathways involved in renal blood flow regulation and kidney disease pathogenesis. A common HBA gene deletion might therefore confer protection against kidney disease by increasing endothelial nitric oxide signaling and decreasing vasoconstriction in response to α-1–adrenergic stimuli. Among Black Americans, HBA copy number varied from 2 to 6; an increase by one HBA gene copy was associated with 14% greater risk of CKD and 32% greater hazard of incident ESKD. This study identifies HBA deletions as protective against CKD and ESKD and highlights the importance of understanding the role of α-globin in renovascular pathophysiology. Background: α-Globin is expressed in endothelial cells of resistance arteries, where it limits endothelial nitric oxide signaling and enhances α-adrenergic–mediated vasoconstriction. α-Globin gene (HBA) copy number is variable in people of African descent and other populations worldwide. Given the protective effect of nitric oxide in the kidney, we hypothesized that HBA copy number would be associated with kidney disease risk. Methods: Community-dwelling Black Americans aged ≥45 years old were enrolled in a national longitudinal cohort from 2003 through 2007. HBA copy number was measured using droplet digital PCR. The prevalence ratio (PR) of CKD and the relative risk (RR) of incident reduced eGFR were calculated using modified Poisson multivariable regression. The hazard ratio (HR) of incident ESKD was calculated using Cox proportional hazards multivariable regression. Results: Among 9908 participants, HBA copy number varied from 2 to 6. In analyses adjusted for demographic, clinical, and genetic risk factors, a one-copy increase in HBA was associated with 14% greater prevalence of CKD (PR, 1.14; 95% CI, 1.07 to 1.21; P<0.0001). While HBA copy number was not associated with incident reduced eGFR (RR, 1.06; 95% CI, 0.94 to 1.19; P=0.38), the hazard of incident ESKD was 32% higher for each additional copy of HBA (HR, 1.32; 95% CI, 1.09 to 1.61; P=0.005). Conclusions: Increasing HBA copy number was associated with a greater prevalence of CKD and incidence of ESKD in a national longitudinal cohort of Black Americans.

1 October 2024 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
ARA. Parker Ruhl
A. Parker Ruhl
RSRuba Shalhoub
Ruba Shalhoub
NJNeal Jeffries
Neal Jeffries
ELEmily M. Limerick
Emily M. Limerick
ALAlexis Leonard
Alexis Leonard
MHMatthew M. Hsieh
Matthew M. Hsieh
Rationale: Sickle cell disease (SCD) is a monogenetic condition with recurring vasoocclusive events causing lifelong pulmonary morbidity and mortality. There is increasing access to curative therapies, such as hematopoietic cell transplant (HCT), for people living with SCD. However, more information on pulmonary function in adults with SCD after HCT is needed to best guide decisions for HCT and post-HCT care. Objectives: To test the hypothesis that forced expiratory volume in 1 second (FEV1) and other pulmonary function testing (PFT) parameters remain stable 3 years after HCT. Methods: People living with SCD undergoing nonmyeloablative HCT in a prospective cohort at the NIH Clinical Center from 2004 to 2019 were evaluated for enrollment. Global Lung Function Initiative reference equations and descriptive statistics were calculated before HCT and annually for 3 years. Six-minute-walk distance (6MWD) testing was performed. Generalized estimating equations were employed to evaluate interindividual changes in PFT parameters and 6MWD. Results: Of 97 patients with SCD undergoing HCT, 41 (42%) were female with median (25th, 75th percentile) age 31.8 (24.8, 38.0) years. Each year of measurement included the following numbers of subjects available for analysis with PFTs: baseline (n = 97), Year 1 (n = 91), Year 2 (n = 72), and Year 3 (n = 55); and the following numbers of subjects available for analysis with 6MWD: baseline (n = 79), Year 1 (n = 73), Year 2 (n = 57), and Year 3 (n = 41). Pre-HCT FEV1 was median (25th, 75th percentile) 68.3% (61.3%, 80.3%) and 69.2% (60.8%, 77.7%) 3 years after HCT, and pre-HCT diffusing capacity of the lung for carbon monoxide (Dl CO) was 60.5% (53.0%, 66.3%) and 64.6% (55.1%, 73.4%) 3 years after HCT. Generalized estimating equations estimated that Dl CO percent predicted increased significantly by 3.7% (95% confidence interval, 1.0%, 6.3%), and the 6MWD significantly increased by 25.9 (6.6, 45.2) meters 3 years after HCT, whereas there was no significant change in percent predicted FEV1 or FVC compared with before HCT. Conclusions: Overall, PFT results remained stable and there was an improvement in Dl CO and 6MWD in this predominantly adult cohort undergoing nonmyeloablative HCT for SCD. Allogeneic HCT for SCD may cease the cycle of vasoocclusive pulmonary injury and prevent continued damage. Multicenter studies are needed to evaluate the long-term lung health effects of HCT for SCD in adults and children.